Jeffrey V Leyton
Jeffrey V Leyton
Introduction: This discourse delves into the intricate connections between the endosomal-lysosomal system and antibody-drug conjugates (ADCs), shedding light on an essential yet less understood dimension of targeted thera...
The safety of canakinumab in systemic juvenile idiopathic arthritis and autoinflammatory diseases in pediatric patients: a multicenter study [0.03%]
卡那单抗治疗儿科患者系统性幼年型关节炎和自身炎症性疾病安全性的多中心研究
Taner Coşkuner,Şengül Çağlayan,Özlem Akgün et al.
Taner Coşkuner et al.
Objective: To evaluate the safety of canakinumab using real-world data in patients with systemic juvenile idiopathic arthritis (sJIA) and autoinflammatory diseases (AID). ...
Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency) [0.03%]
血友病B(先天性凝血因子IX缺乏)患者的etranacogene dezaparvovec基因治疗
Tro Sekayan,Dana H Simmons,Annette von Drygalski
Tro Sekayan
Introduction: Congenital hemophilia B (HB) is an X-linked bleeding disorder resulting in Factor IX (FIX) deficiency and bleeding of variable severity. There is no cure for HB. Typical management consists of prophylactic i...
Antibody drug conjugates for glioblastoma: current progress towards clinical use [0.03%]
抗体偶联药物在胶质母细胞瘤中的应用：临床研究的最新进展
Hui K Gan,Sagun Parakh,Laura D Osellame et al.
Hui K Gan et al.
Introduction: Antibody drug conjugates (ADCs) are now a proven therapeutic class for many cancers, combining highly specific targeting with the potency of high effective payloads. This review summarizes the experience wit...
Novel formats of antibody conjugates: recent advances in payload diversity, conjugation, and linker chemistry [0.03%]
抗体偶联物的新格式：有效负载多样性、偶联和连接器化学的最新进展
Tomohiro Fujii,Yutaka Matsuda
Tomohiro Fujii
Introduction: In the field of bioconjugates, the focus on antibody - drug conjugates (ADCs) with novel payloads beyond the traditional categories of potent cytotoxic agents is increasing. These innovative ADCs exhibit var...
What role can LAG-3-blocking antibodies play in melanoma therapy? [0.03%]
LAG-3阻断型抗体在黑色素瘤治疗中的作用机制及其临床研究进展
Piotr Rutkowski,Paulina Jagodzińska-Mucha
Piotr Rutkowski
Mariam Nikolaishvili,Vito Di Lernia
Mariam Nikolaishvili
Introduction: Psoriasis is a multifactorial, immune-mediated condition with predominant skin involvement. It may develop at any age. In one-third of patients, the first symptoms of psoriasis start during childhood or adol...
Antibody-drug conjugates targeting HER2-mutant or HER2-(non) amplified solid tumors: is HER2 an agnostic target? [0.03%]
靶向HER2突变或HER2扩增实体瘤的抗体药物偶联物：HER2是一个非特异性靶标吗？
Lorenzo Guidi,Carmine Valenza,Dario Trapani et al.
Lorenzo Guidi et al.
Antibody-drug conjugates in oncology: insights into Current challenges [0.03%]
抗体-药物偶联物在肿瘤学中的应用：目前面临的挑战
Ahmad Z Al Meslamani,Mohammad F Bostanudin
Ahmad Z Al Meslamani